GLP-1 Receptor Agonists for Fatty Liver Disease

Introduction to GLP-1 Receptor Agonists

The American Gastroenterological Association recommends semaglutide as the preferred GLP-1 receptor agonist for treating NASH, with demonstrated histologic improvement and NASH resolution in 59% of patients at the highest studied dose 1, 2, 5
The American Diabetes Association guidelines suggest using GLP-1 receptor agonists according to standard diabetes indications for patients with type 2 diabetes and NAFLD, as they improve cardiometabolic profile and reverse steatosis 1, 4

Semaglutide achieved NASH resolution without worsening fibrosis in 59% vs 17% with placebo, and reduced fibrosis progression in a 72-week trial of 320 patients with biopsy-proven NASH 1, 2, 5
Liraglutide showed reversal of steatohepatitis and slower fibrosis progression in 52 patients over 12 months, with improvement in steatosis proportional to weight loss 1, 4, 5
Dulaglutide has limited evidence showing reduced liver fat content and transaminases in small studies 2, 6

Pioglitazone remains an evidence-based option with resolution of NASH in 47% vs 21% with placebo, and reversal of advanced fibrosis 1, 2, 5
SGLT2 inhibitors reduce steatosis by approximately 20% but lack histological improvement data 3
Vitamin E improved steatohepatitis in non-diabetic patients with biopsy-proven NASH but had mixed results in patients with type 2 diabetes 1, 4, 5

Semaglutide dosing starts at 0.25mg weekly and titrates up to 2.4mg weekly for maintenance, with slow titration essential to minimize gastrointestinal side effects 8

Common adverse effects of GLP-1 receptor agonists include nausea, vomiting, diarrhea, and constipation, which are dose-dependent and typically improve with continued use 1, 2, 5, 8
Serious but rare risks requiring monitoring include pancreatitis, acute gallbladder disease, acute kidney injury, and hypoglycemia risk if combined with insulin or sulfonylureas 7, 8

The hepatic benefits of GLP-1 receptor agonists are primarily mediated through substantial weight loss rather than direct hepatic effects, with semaglutide reducing hepatic steatosis through weight loss, improved energy balance, and decreased intrahepatic triglyceride content 3, 7, 8